Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M

LIFECORE BIOMEDICAL, INC. DE

2025-Q3 EPS reported -$1.24 revenue$92,423,000

Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.
Net loss of $14.8M ($0.47 diluted loss per share) vs prior-year net income of $15.6M including $21M non-cash debt derivative gain.
Adjusted EBITDA $5.7M, down from $6.4M YoY; gross profit fell to $9.8M from $11.9M.
Sold unused high-speed isolator filler for $17M; $7M received at closing, remainder over 18 months. Signed multiple new development agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.